Objectives: This Italian Society of Pediatric Allergology and Immunology (SIAIP) document aims to provide an evidence-based age-specific framework for the diagnosis, classification, and practical management of AR in children and adolescents, while addressing the limitations of existing less granular guidelines. Methods: A dedicated SIAIP experts' board reviewed current scientific literature, integrated updated epidemiological data, revised classifications, and emerging evidence on allergen immunotherapy. It incorporates the ARIA 2026 guidelines and adapts them to the clinical challenges and age-specific considerations relevant to pediatric practice. The board of qualified experts and a panel of multidisciplinary clinicians discussed and approved the document. Results: This document covers the epidemiology, pathophysiology, and diagnosis of AR in children and adolescents. It provides detailed stepwise pharmacologic recommendations and discusses the role of allergen immunotherapy (AIT), taking age-specific factors and complementary therapies into account. Evidence-based statements and practical management algorithms aim to optimize diagnostic pathways and therapeutic interventions. Conclusions: This SIAIP document offers clinically actionable guidance for healthcare professionals. It emphasizes early diagnosis, stepwise treatment strategies, and the disease-modifying role of AIT, aiming to enhance diagnostic accuracy, streamline management, and ultimately improve the long-term health and well-being of affected children and adolescents.

A Current Evidence Review From the Italian Society of Pediatric Allergology and Immunology (SIAIP) on Practical Management of Allergic Rhinitis in Children and Adolescents.

Sara Manti;
2026-01-01

Abstract

Objectives: This Italian Society of Pediatric Allergology and Immunology (SIAIP) document aims to provide an evidence-based age-specific framework for the diagnosis, classification, and practical management of AR in children and adolescents, while addressing the limitations of existing less granular guidelines. Methods: A dedicated SIAIP experts' board reviewed current scientific literature, integrated updated epidemiological data, revised classifications, and emerging evidence on allergen immunotherapy. It incorporates the ARIA 2026 guidelines and adapts them to the clinical challenges and age-specific considerations relevant to pediatric practice. The board of qualified experts and a panel of multidisciplinary clinicians discussed and approved the document. Results: This document covers the epidemiology, pathophysiology, and diagnosis of AR in children and adolescents. It provides detailed stepwise pharmacologic recommendations and discusses the role of allergen immunotherapy (AIT), taking age-specific factors and complementary therapies into account. Evidence-based statements and practical management algorithms aim to optimize diagnostic pathways and therapeutic interventions. Conclusions: This SIAIP document offers clinically actionable guidance for healthcare professionals. It emphasizes early diagnosis, stepwise treatment strategies, and the disease-modifying role of AIT, aiming to enhance diagnostic accuracy, streamline management, and ultimately improve the long-term health and well-being of affected children and adolescents.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11570/3366549
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact